Merck's Keytruda Approved in EU; Analyst Upgrades Price Target
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2026
0mins
Should l Buy MRK?
Source: seekingalpha
Merck & Co Inc's stock rose by 3.00% as it reached a 20-day high, reflecting strong investor interest following recent positive developments.
The company has been recognized as one of the best dividend stocks, and JPMorgan analyst Chris Schott raised Merck's price target from $125 to $135 while maintaining an Overweight rating. Additionally, Merck's KEYTRUDA received approval in the EU for treating platinum-resistant ovarian cancer, marking a significant milestone that is expected to enhance its sales potential across Europe.
These developments not only bolster Merck's market position but also highlight its commitment to innovation in oncology, which could lead to increased revenue and shareholder returns in the future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to fall
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 123.180
Low
95.00
Averages
119.53
High
139.00
Current: 123.180
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Merck & Co. Recognized as One of the Best Dividend Stocks to Buy Now
- Dividend Stock Recognition: Merck & Co. has been listed among the 15 Best Consistent Dividend Stocks, highlighting its stable cash flow and shareholder return capabilities, which attract investor interest.
- Analyst Rating Upgrade: JPMorgan analyst Chris Schott raised Merck's price target from $125 to $135 while maintaining an Overweight rating, indicating market confidence in its future performance ahead of the upcoming earnings report.
- Key Drug Approval: Merck's KEYTRUDA has been approved in the EU for treating platinum-resistant ovarian cancer patients, becoming the first PD-1 inhibitor-based treatment option, which is expected to significantly boost its sales potential in the European market.
- Market Coverage Expansion: The approval of KEYTRUDA allows it to be marketed across all 27 EU member states, as well as Iceland, Liechtenstein, and Norway, with local reimbursement processes expected to accelerate market penetration, further solidifying Merck's position in the global healthcare market.
See More
Merck Initiates Cash Tender Offer for Terns Pharmaceuticals
- Tender Offer Launch: Merck & Co Inc. has initiated a cash tender offer to acquire all outstanding shares of Terns Pharmaceuticals at $53 per share, indicating a strong acquisition intent that is expected to enhance Merck's market position in the biopharmaceutical sector.
- Transaction Background: This acquisition follows a definitive agreement made on March 25, 2026, where Merck agreed to acquire Terns, highlighting its strategic focus on innovative drug development and the aim to enhance R&D efficiency through resource integration.
- Transaction Timeline: The cash tender offer is set to expire on May 4, 2026, with the transaction expected to close in the second quarter of 2026, reflecting Merck's commitment to quickly integrate Terns' operations to realize synergies.
- Market Reaction: Terns' shares closed at $52.78 on Monday, up 0.11%, indicating a positive market sentiment towards the acquisition, which may further drive Terns' stock price closer to the acquisition price.
See More
CDC Vaccine Advisory Committee Receives New Operating Rules
- Expanded Committee Role: HHS Secretary Robert F. Kennedy Jr. has signed new rules that significantly expand the CDC Vaccine Advisory Committee's role, moving beyond domestic vaccine recommendations to encompass a broader range of public health initiatives, aiming to enhance the comprehensiveness and effectiveness of vaccine policy.
- Focus on Safety Research: The new rules emphasize identifying gaps in vaccine safety research, including adverse effects post-vaccination, reflecting a heightened concern for vaccine safety that could influence public trust and acceptance, thereby impacting vaccination rates.
- Assessment of New Technologies: The committee is now tasked with considering novel vaccine platforms, such as mRNA vaccines, which were utilized in COVID-19 vaccines, indicating a focus on future vaccine technology developments that may drive innovation and progress in vaccine research.
- Transparent Decision-Making: The new rules mandate a transparent, evidence-driven decision-making process for the committee, requiring the review of clinical data and expert consultations to ensure the scientific validity of vaccine recommendations, which will help enhance public trust in CDC guidance.
See More
MERCK & CO INC: CEO ROBERT M. DAVIS TO RECEIVE $20.8 MILLION IN TOTAL COMPENSATION FOR 2025 - FILING
CEO Compensation: Merck & Co. CEO Robert M. Davis is set to receive a total compensation of $20.8 million for the year 2025.
Filing Details: This compensation figure was disclosed in a recent filing, highlighting the financial aspects of executive pay within the company.
See More
Terns Pharmaceuticals Acquired by Merck, Share Price Surges
- Acquisition Agreement: On March 25, Terns Pharmaceuticals announced a definitive agreement with Merck, under which Merck will acquire Terns for $53 per share in cash, totaling approximately $6.7 billion, representing a 42% premium that significantly boosted Terns' share price by over 25% in March.
- Core Drug Value: Terns' lead drug candidate, TERN-701, is currently in a phase 1/2 clinical trial and has received FDA Orphan Drug Designation, which is expected to become a major revenue driver, enhancing the strategic significance of the acquisition.
- Positive Market Reaction: Analysts view the acquisition as a “steal” for Merck, as TERN-701 has the potential to be a strong revenue source, thereby strengthening Merck's position in oncology.
- Shareholder Benefit Assurance: Although the deal requires approval from a majority of Terns' shareholders, the substantial premium makes it likely to close within the current quarter, ensuring Terns' shareholders receive a healthy return.
See More
U.S. Economic Outlook Dims Amid Iran Tensions
- Market Weakness: The S&P 500 index showed significant weakness as President Trump's deadline for Iran approached, with most of the session in the red, reflecting investor concerns over economic prospects amid declining consumer confidence and rising inflation.
- Retail Sector Decline: Walmart's 3.3% drop indicates that even budget-conscious consumers may cut back on spending during an economic downturn, suggesting a deteriorating overall consumer health that could have long-term implications for the retail sector.
- Cruise Industry Struggles: Shares of Royal Caribbean, Norwegian Cruise Line, and Carnival fell nearly 3%, 3.3%, and 2.96% respectively, indicating a potential decline in consumer demand for travel post-pandemic, which raises further concerns about economic recovery.
- Pharmaceutical Stocks Underperform: Merck, Pfizer, and AbbVie saw declines of 1.3%, 2.6%, and 0.2%, respectively, highlighting inflationary pressures and the dual challenges of economic slowdown and rising costs faced by the pharmaceutical industry.
See More
Merck & Co. Recognized as One of the Best Dividend Stocks to Buy Now
- Dividend Stock Recognition: Merck & Co. has been listed among the 15 Best Consistent Dividend Stocks, highlighting its stable cash flow and shareholder return capabilities, which attract investor interest.
- Analyst Rating Upgrade: JPMorgan analyst Chris Schott raised Merck's price target from $125 to $135 while maintaining an Overweight rating, indicating market confidence in its future performance ahead of the upcoming earnings report.
- Key Drug Approval: Merck's KEYTRUDA has been approved in the EU for treating platinum-resistant ovarian cancer patients, becoming the first PD-1 inhibitor-based treatment option, which is expected to significantly boost its sales potential in the European market.
- Market Coverage Expansion: The approval of KEYTRUDA allows it to be marketed across all 27 EU member states, as well as Iceland, Liechtenstein, and Norway, with local reimbursement processes expected to accelerate market penetration, further solidifying Merck's position in the global healthcare market.
See More
Merck Initiates Cash Tender Offer for Terns Pharmaceuticals
- Tender Offer Launch: Merck & Co Inc. has initiated a cash tender offer to acquire all outstanding shares of Terns Pharmaceuticals at $53 per share, indicating a strong acquisition intent that is expected to enhance Merck's market position in the biopharmaceutical sector.
- Transaction Background: This acquisition follows a definitive agreement made on March 25, 2026, where Merck agreed to acquire Terns, highlighting its strategic focus on innovative drug development and the aim to enhance R&D efficiency through resource integration.
- Transaction Timeline: The cash tender offer is set to expire on May 4, 2026, with the transaction expected to close in the second quarter of 2026, reflecting Merck's commitment to quickly integrate Terns' operations to realize synergies.
- Market Reaction: Terns' shares closed at $52.78 on Monday, up 0.11%, indicating a positive market sentiment towards the acquisition, which may further drive Terns' stock price closer to the acquisition price.
See More
CDC Vaccine Advisory Committee Receives New Operating Rules
- Expanded Committee Role: HHS Secretary Robert F. Kennedy Jr. has signed new rules that significantly expand the CDC Vaccine Advisory Committee's role, moving beyond domestic vaccine recommendations to encompass a broader range of public health initiatives, aiming to enhance the comprehensiveness and effectiveness of vaccine policy.
- Focus on Safety Research: The new rules emphasize identifying gaps in vaccine safety research, including adverse effects post-vaccination, reflecting a heightened concern for vaccine safety that could influence public trust and acceptance, thereby impacting vaccination rates.
- Assessment of New Technologies: The committee is now tasked with considering novel vaccine platforms, such as mRNA vaccines, which were utilized in COVID-19 vaccines, indicating a focus on future vaccine technology developments that may drive innovation and progress in vaccine research.
- Transparent Decision-Making: The new rules mandate a transparent, evidence-driven decision-making process for the committee, requiring the review of clinical data and expert consultations to ensure the scientific validity of vaccine recommendations, which will help enhance public trust in CDC guidance.
See More
MERCK & CO INC: CEO ROBERT M. DAVIS TO RECEIVE $20.8 MILLION IN TOTAL COMPENSATION FOR 2025 - FILING
CEO Compensation: Merck & Co. CEO Robert M. Davis is set to receive a total compensation of $20.8 million for the year 2025.
Filing Details: This compensation figure was disclosed in a recent filing, highlighting the financial aspects of executive pay within the company.
See More
Terns Pharmaceuticals Acquired by Merck, Share Price Surges
- Acquisition Agreement: On March 25, Terns Pharmaceuticals announced a definitive agreement with Merck, under which Merck will acquire Terns for $53 per share in cash, totaling approximately $6.7 billion, representing a 42% premium that significantly boosted Terns' share price by over 25% in March.
- Core Drug Value: Terns' lead drug candidate, TERN-701, is currently in a phase 1/2 clinical trial and has received FDA Orphan Drug Designation, which is expected to become a major revenue driver, enhancing the strategic significance of the acquisition.
- Positive Market Reaction: Analysts view the acquisition as a “steal” for Merck, as TERN-701 has the potential to be a strong revenue source, thereby strengthening Merck's position in oncology.
- Shareholder Benefit Assurance: Although the deal requires approval from a majority of Terns' shareholders, the substantial premium makes it likely to close within the current quarter, ensuring Terns' shareholders receive a healthy return.
See More
U.S. Economic Outlook Dims Amid Iran Tensions
- Market Weakness: The S&P 500 index showed significant weakness as President Trump's deadline for Iran approached, with most of the session in the red, reflecting investor concerns over economic prospects amid declining consumer confidence and rising inflation.
- Retail Sector Decline: Walmart's 3.3% drop indicates that even budget-conscious consumers may cut back on spending during an economic downturn, suggesting a deteriorating overall consumer health that could have long-term implications for the retail sector.
- Cruise Industry Struggles: Shares of Royal Caribbean, Norwegian Cruise Line, and Carnival fell nearly 3%, 3.3%, and 2.96% respectively, indicating a potential decline in consumer demand for travel post-pandemic, which raises further concerns about economic recovery.
- Pharmaceutical Stocks Underperform: Merck, Pfizer, and AbbVie saw declines of 1.3%, 2.6%, and 0.2%, respectively, highlighting inflationary pressures and the dual challenges of economic slowdown and rising costs faced by the pharmaceutical industry.
See More
